Bézay N, Wagner L, Kadlecek V, et al. Optimisation of dose level and vaccination schedule for the VLA15 Lyme borreliosis vaccine candidate among healthy adults: two randomised, observer-blind, placebo-controlled, multicentre, phase 2 studies. Lancet In...

Since late 2023, more than 10 000 locally acquired cases of Oropouche virus have been reported in the Americas.1 Here, we describe the first cluster of Oropouche virus imported into France from Cuba, where transmission has been ongoing since at least M...

The substantial decline in the global burden of diarrhoeal diseases since 1990, particularly in children younger than 5 years, supports the effectiveness of health interventions such as oral rehydration therapy, enhanced water, sanitation, and hygiene ...

An acceptable safety and tolerability profile, confirmed parasiticidal activity, and a long half-life support progression of MMV533 into clinical trials in patients with malaria as a component of new antimalarial combination therapies.

Using the latest data from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD), the GBD 2021 Diarrhoeal Diseases Collaborators1 have published updated estimates of the global diarrhoeal disease burden in The Lancet Infectious Diseases...

In the past two decades artemisinin-based combination therapies have been the first-line therapy for patients with uncomplicated Plasmodium falciparum malaria globally and are the cornerstone for malaria case management in endemic countries with more t...